Minigastrin I (human)

CAS No. 60748-07-4

Minigastrin I (human)( ——— )

Catalog No. M40217 CAS No. 60748-07-4

Minigastrin is an acidic peptide. Minigastrin can be used to study peptidepeptide interaction.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG Get Quote Get Quote
50MG Get Quote Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Minigastrin I (human)
  • Note
    Research use only, not for human use.
  • Brief Description
    Minigastrin is an acidic peptide. Minigastrin can be used to study peptidepeptide interaction.
  • Description
    Minigastrin is an acidic peptide. Minigastrin can be used to study peptidepeptide interaction.
  • In Vitro
    ———
  • In Vivo
    ———
  • Synonyms
    ———
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ———
  • Research Area
    ———
  • Indication
    ———

Chemical Information

  • CAS Number
    60748-07-4
  • Formula Weight
    1645.66
  • Molecular Formula
    C74H99N15O26S
  • Purity
    >98% (HPLC)
  • Solubility
    ———
  • SMILES
    ———
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Woods AS,et al. A study of peptide--peptide interaction by matrix-assisted laser desorption/ionization. J Am Soc Mass Spectrom. 2001;12(1):88-96. ?
molnova catalog
related products
  • 3,8-dihydroxy-1-meth...

    3,8-dihydroxy-1-methylanthraquinone-2-carboxylicacid

  • CAY10781

    CAY10781 is an inhibitor of the protein-protein interaction between neuropilin-1 (NRP-1) and VEGF-A.1It inhibits the interaction by 43% when used at a concentration of 12.5 μM. CAY10781 also inhibits VEGF-A-induced phosphorylation of VEGFR2 in catecholamine A-differentiated (CAD) cells when used at the same concentration.

  • Arg-Gly-Glu-Ser(TFA)

    Arg-gly-glu -Ser(TFA) is a RGD related polypeptide that controls the inhibition of fibrinogen binding to activated platelets by RGDS.